New market expansion VivoSim Labs has expanded offices to China and announced its first commercial sales in China, signaling a strong international growth trajectory and a potential entry point for regional partners, distributors, and contract research organizations seeking NAM-based preclinical services.

NAMs leadership The company positions itself as a pioneer in New Approach Methodologies with NAMkind tissue models, offering a distinctive value proposition for pharma and biotech clients seeking more predictive human-relevant data to de-risk early drug development and improve clinic translation.

AI integration Launched an AI prediction tool leveraging NAMkind intestinal models to forecast drug-induced diarrhea, creating a cross-sell opportunity for clients needing integrated in silico and in vitro safety assessments to streamline decision-making.

Evidence & recognition Participation in industry events and a blue ribbon award for NAMkind intestine at Digestive Disease Week enhances credibility, enabling sales teams to approach potential customers with validated efficacy and market validation claims.

Scale & partnerships With substantial funding and a mid-market size, VivoSim Labs can pursue strategic partnerships, licensing, and channel partnerships to scale NAM services, data offerings, and potential collaboration on platform integrations with larger CROs and biopharma.